Xi'an, China

Xiangmin Yang


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2012-2018

where 'Filed Patents' based on already Granted Patents

2 patents (USPTO):

Title: Xiangmin Yang: Innovator in Antibody Research

Introduction

Xiangmin Yang is a prominent inventor based in Xi'an, China. He has made significant contributions to the field of antibody research, holding a total of 2 patents. His work focuses on innovative solutions for diseases related to CD147 expression.

Latest Patents

Xiangmin Yang's latest patents include a groundbreaking development titled "Human-mouse chimeric anti-CD147 antibody with non-fucosylated glycosylation." This patent discloses a nucleotide sequence comprising specific sequences and describes an antibody that binds to the extracellular region of human CD147. The antibody is characterized by a glycoform that lacks both fucose and xylose residues, along with a pharmaceutical composition for treating CD147 expression-related diseases. Another notable patent is "Crystal structure of CD147 extracellular region and use thereof," which provides a 3D structure of the CD147 extracellular region. This structure is instrumental in determining the active site of CD147 through computer modeling and molecular docking methods, aiding in structure-based drug design.

Career Highlights

Xiangmin Yang has worked at esteemed institutions, including the Fourth Military Medical University. His research has significantly advanced the understanding of antibody interactions and their applications in medicine.

Collaborations

Throughout his career, Xiangmin Yang has collaborated with notable colleagues such as Zhinan Chen and Zheng Zhang. Their joint efforts have contributed to the advancement of research in the field of antibody development.

Conclusion

Xiangmin Yang's innovative work in antibody research has led to valuable patents that hold promise for medical advancements. His contributions continue to impact the scientific community and pave the way for future developments in treating diseases related to CD147 expression.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…